Archive for the ‘marijuana news’ Category

Invest Caribbean Partners With The Ritzury Group To Launch Green Glove Bespoke Service For Barbados’ Cannabis Sector

CaribPR Wire, NEW YORK, NY, Fri. Feb. 12, 2021: Get ready for the one-stop Green Glove Bespoke Service for Barbados’ cannabis sector.

Invest Caribbean, the global private sector investment agency of the Caribbean, has partnered with the international project services Bespoke Division of the Barbados-based company, The Ritzury Group, to launch the service for investors seeking to invest in the country’s new medical marijuana sector, which opened officially for business in January.

According to ICN’s CEO, Felicia J. Persaud, and The Ritzury Group’s Executive Chairman, Danielle Corbin, the Green Glove Bespoke Service offerings will include all ground-up project development services relating to Barbados’ new cannabis sector. These will include policy research, feasibility studies, competitive analysis reports, licensing applications, globally accepted business plan services, matching foreign investors with local entrepreneurs, scouting and procurement of project locations, company registration, legal and operations management services, capital raise and branding and marketing services – all under one roof.

“Teaming with the Ritzury Group will allow ICN to expand its current service offerings in the cannabis sector, into growing the medical marijuana sector in Barbados,” said Persaud. “This is intended to help investors who are anxious to invest in this market but are confused about where to begin or how to collaborate with local entrepreneurs. Our Green Glove service is intended to take the hassle out of the process and provide one-stop shopping at its best.”

“This is a new and exciting industry for Barbados,” said Corbin. “We have seen an exponential increase of interest and activity in this sector, especially in recent months, and this powerful partnership will help aid in making this sector internationally lauded, while providing ease of doing business in this sector here for the savvy investor.”

Ritzury and ICN, which recently completed a historic global Caribbean inauguration celebration of the US’ first Black Caribbean American Vice President, Kamala Harris, featuring a number of Barbados entertainers, will also simultaneously focus on offering the same services to investors and governments in the health care, manufacturing, real estate and energy sectors.

The companies are also currently ready to work with middle to large operating ‘distressed’ companies that are seeking growth capital – debt and/ or equity or some form of liquidity, whether through partial sale, recapitalization or via a management buy-in (MBI) or a management buyout (MBO).

For more information contact ICN and Ritzury at or


Invest Caribbean was founded in 2011 by Caribbean-born immigrant, Felicia J. Persaud, and is the global private sector investment agency of the Caribbean. ICN provides specialized, fundraising support for project developers and governments, and works alongside private equity and debt funders to add depth, breadth and responsiveness to clients fundraising and investor relations efforts in the real estate, cannabis, health care, energy, mining and manufacturing sectors. The company, through CaribPR Wire and Hard Beat Communications, also offers global content distribution including SEC filings and IR webcasting and teleconferencing as well as customized digital experiences and creatives. For more information see


The Ritzury Group – Bespoke Division is a Barbados-based international project services division with a focus on project design and development, project operations management and investor – client relations. The Bespoke Division works hand in hand with project shareholders globally to produce high revenue, sustainable projects. The Group has evaluated, as of December 2020, over USD 9.3 billion in global Client Projects. For more information see


Click Here for More Information »

Medicinal Genomics Partners with Analogic Solutions for Distribution of its Cannabis Genomic Breeding, Optimization, and Testing Platform to the Caribbean

Leading local firm driving adoption of biotechnology for yield, safety, and consistency throughout the region

BEVERLY, Mass., Jan. 6, 2020 /PRNewswire-HISPANIC PR WIRE/ — Medicinal Genomics Corp. (MGC), a pioneer in genomics and blockchain technology to improve the yield, safety, and transparency of cannabis, today announced its partnership with Analogic Solutions as its distributor of record for the Caribbean region. Analogic is headquartered in Trinidad and is at the forefront of supplying the latest cannabis breeding and testing technology to the up-and-coming industry throughout the islands.

Following Jamaica’s lead, many other Caribbean nations, including Trinidad, are also implementing decriminalization reforms and establishing medical and adult use cannabis programs. But just as in many other global nascent markets, including the U.S., regulations lag advances made by science and technology.

“Education is critical to the acceleration of our learning curve,” said Lorca Gatcliffe-Farah, Analogic Solutions’ CEO. “We chose MGC because their technology is the most advanced and also because of the human energy that they bring to their relationships. This is a valuable element to us. MGC goes beyond technological rigidity and the predictions of future growth, instead, they are always conscientious of the impact that our collective efforts are having on people’s lives. Our in-house expertise with Genomics coupled with our intent to develop the Caribbean region created the right environment for this partnership to flourish.”

“Unlike many local firms, Analogic has a global perspective on the industry, and as such, are advocates for more education and the latest methods for economically producing clean and consistent products—not simply because regulations mandate it, but because that’s one of the prerequisites for a thriving medical market,” said Brendan McKernan, CEO of Medicinal Genomics. “They also recognize that a lack of regulation supports a thriving illegal market, and how products that are certified to be safe and consistent are the ultimate differentiator, particularly when people’s lives are at risk. Everything about Analogic Solutions makes them the right partner for us.”

Given the ideal growing conditions and abundance of heritage cultivars in the Caribbean, all predictors point to robust growth for the region, which Analogic Solutions is fully intending to capitalize on. “Given the scale of some of our customers’ operations, we quickly realized that we had to offer a full testing and breeding solution,” Gatcliffe-Farah said. “Our customers are importing experts from around the world, and we see the value in improving our offerings and staff to locally achieve the same results.”

About Analogic Solutions
Analogic Solutions is a Trinidad and Tobago based Company who has been the sole distributer within the Caribbean region for Agilent Technologies’ Genomics, Life Sciences and Chemical Analysis Products Group (formerly Hewlett Packard) since 1998. The Company grew from having two employees at the start to now having three departments consisting of fifteen employees and four support service providers, all involved in the continuous and systematic supply and service of Precision Life Sciences Solutions to our customers within the Caribbean region.  Analogic has also partnered with a host of specialized and reputable Chemical Analysis Solutions Providers in order to meet the goal of giving our customers access to the very best tools, supplies and technological support for their business operations. Recently the Company established a Branch Office in Jamaica which is a part of the continuous development plans that is being pursued for the year 2020 and beyond.

About Medicinal Genomics Corporation
Medicinal Genomics Corporation is a pioneer in advancing the genomics of cannabis to build a stronger scientific foundation for cannabis-based products. The company’s unmatched expertise in genetic science helps cultivators, dispensaries and testing laboratories characterize and understand the quality and consistency of cannabis to ensure patients and consumers have access to consistently safe, high quality cannabis. To support their mission, Medicinal Genomics also produces CannMed, an annual gathering of cannabis leaders, dedicated to the scientific advancement of the cannabis industry, and Kannapedia, the world’s most complete public cannabis cultivar database. For more information, please visit

Click Here for More Information »

The Medicinal Cannabis Authority of St. Vincent and the Grenadines selects Ample Organics for National Cannabis Tracking System

TORONTO, Dec. 5, 2019 /CNW/ – Ample Organics Inc. and the Medicinal Cannabis Authority (”MCA”) in Saint Vincent and the Grenadines, together, are proud to announce their partnership to strengthen the medicinal cannabis industry in Saint Vincent and the Grenadines by activating AmpleCentral™ — the world’s first national Cannabis Tracking System built for regulators.

Leveraging its extensive cannabis industry domain expertise at the federally regulated level, Ample Organics will be providing sound industry-wide advice to the MCA as the medicinal cannabis industry emerges in St. Vincent and the Grenadines. Together, a two-phase approach will be established to facilitate the rapid rollout of the new medicinal cannabis program. Initially, the Ample Organics seed-to-sale software platform will be deployed to empower the MCA, along with physicians and pharmacists, to register and service medicinal cannabis patients. This software platform is the trusted solution serving the world’s largest cannabis companies and over 70% of Canadian License Holders. Concurrently, Ample Organics will be working closely with the MCA and stakeholders to customize and deploy AmpleCentral™ specifically for St. Vincent and the Grenadines. A first-of-its-kind jurisdictional track-and-trace database, AmpleCentral™ is designed for governments to facilitate sophisticated reporting and to assist regulators with ensuring compliance, verifying product quantity and quality, taxation, and preventing diversion and inversion. This technology connects data points across the national cannabis supply chain, providing regulators with the information necessary to assure public, product, and patient safety.

“We believe that this is a hugely important milestone,” says John Prentice, President and CEO of Ample Organics. “It will be the very first implementation of a true national tracking system within the cannabis industry anywhere in the world, and it has allowed us the opportunity to engage with government agencies across the globe as new markets arise. With the support of the Government of Canada, we are building AmpleCentral™ to empower other federal governments to regulate, monitor, and monetize their cannabis industries effectively. This public-private partnership enables the MCA to leverage our unique and extensive expertise operating compliance systems on a national scale. St. Vincent and the Grenadines’ well-thought-out and comprehensive regulatory framework, should, and will, serve as a model for the CARICOM nations and any other national jurisdiction considering a forward-thinking cannabis program.”

“We are establishing this industry with the mantra that a ‘Medicinal Cannabis Industry begins with Science and Technology,’” says Dr. Jerrol Thompson, CEO of the Medicinal Cannabis Authority. “That is why we are taking this bold lead to invest, and an early stage, in a Central Inventory Management Traceability system that will: (1) eliminate diversion; (2) facilitate real-time supply chain reporting; (3) support our banking solution and compliance regime; (4) and provide a safety net for product recall.”

Over the past few months, as part of a government mandate, the MCA has rolled out an innovative country-wide education program providing theoretical and practical training to indoor and outdoor cultivators, including industry best-practices and Good Agricultural and Collection Practices (GACP). Ample Organics is dedicated to sharing the responsibility to foster an educated and informed cannabis industry, and therefore, will provide AmpleLearn™ as a way to administer education programs to enhance the training and education available.

“One of the reasons we have chosen to work with the Medicinal Cannabis Authority in St. Vincent and the Grenadines is their commitment to ensuring a successful cannabis industry through education,” says Tom Ritchie, VP of Accounts & Education at Ample Organics. “It is vital to us that traditional cultivators have proper educational tools available to them so that they, too, can thrive in a regulated cannabis industry. As the first in the world to develop a certification program for seed-to-sale software operators, we have the know-how to help administer education and training programs by leveraging AmpleLearn™, our online Learning Management System. We are committed to supporting the initiatives that the MCA is launching and look forward to the future.”

About Ample Organics:
Founded in 2014, Ample Organics is adopted by more Canadian Licensed Holders than any other cannabis software solution. A complete ecosystem for cannabis businesses, the technology platform makes compliance easy by tracking individual plants from seed to consumer and reporting every detail of the growth, production, and sales processes. Our team of cannabis industry and technology experts designed the platform to facilitate compliance and transparency, while enhancing overall business efficiency and operational intelligence. The software continues to be the most trusted solution for cannabis producers, manufacturers, distributors, physicians, clinics, laboratories, retailers, and educators.

About the Medicinal Cannabis Authority:
The Medicinal Cannabis Authority was established through the Medicinal Cannabis Industry Act, 2018. It is a body corporate with a mandate to regulate the cultivation, supply, possession, production and use of cannabis for medicinal purposes. This mandate forms part of the Government of St. Vincent and the Grenadines’ vision to establish a well-regulated export-oriented medicinal cannabis industry.
Visit MCA.VC.

Click Here for More Information »

Cansortium Announces Opening of its Second Fluent™ Medical Marijuana Dispensary in Puerto Rico

MIAMI, Aug. 12, 2019 /PRNewswire-HISPANIC PR WIRE/ — Cansortium Inc. (”Cansortium” or the “Company”) (CSE: TIUM), a vertically-integrated, global provider of premium-quality medical cannabis operating under the Fluent™ brand, continues to expand its global retail footprint with the July 25 opening of a new Fluent dispensary in a prime location at the San Patricio Town Center in Calle Tabonuco, Guaynabo, Puerto Rico.

Cansortium Inc.

Cansortium’s Chief Executive Officer Jose Hidalgo noted, “The opening of our second Fluent dispensary in Puerto Rico is further evidence that we are executing our growth plan by steadily expanding our dispensary network to enhance access to our premium-quality Fluent cannabis products for medical marijuana patients in key markets. Puerto Rico has more than 92,000 certified medical marijuana patients and offers reciprocity to all medical cannabis card holders from any US state.

“In addition to our two dispensaries in Puerto Rico, we operate 15 Fluent dispensaries in Florida with plans to have 30 in operation or secured by the end of 2019, one Fluent dispensary in Pennsylvania with plans to open two more, and we offer home delivery across the entire state of Texas where we are one of only three licensed medical marijuana providers. We are excited to bring our high-quality consistently-formulated Fluent products to more customers in Puerto Rico and other key markets, and to help consumers in those markets become Fluent in the benefits of cannabis.”

The new 2,200 square-foot dispensary is the Company’s second in Puerto Rico, joining the company’s San Juan dispensary that opened in January 2018. Conveniently located in an upscale mall in San Patricio, one of the most exclusive neighborhoods along the northern coast of Puerto Rico, the location is easily accessed from the PR-2, PR-23 and PR-20 highways. In celebration of its opening, the San Patricio dispensary is offering specials during its first several weeks of operation as it builds up its inventory to represent a complete assortment of Fluent-branded products.

The Fluent brand continually strives to set the standard for premium quality, consistently-formulated cannabis products. Each of the Company’s dispensaries will carry a complete assortment of Fluent premium dried flower, and full spectrum concentrates and cartridges, as well as creams, drops, capsules and suppositories. All Fluent products in the Company’s Puerto Rican dispensaries use high-quality cannabis that is cultivated, processed and packaged in our state-of-the-art Puerto Rican facilities in strict compliance with the country’s medical marijuana regulations. For consumers, the sleek, modern dispensaries provide a warm, welcoming, professional environment, with private consultation rooms and knowledgeable staff who carefully guide patients in selecting the right products and carefully safeguard patient privacy.

For a complete list of Fluent dispensary locations, current promotions and rewards programs and hours of operation, or to explore the entire Fluent product line and place an online order for home delivery, visit

Cansortium is a global medical cannabis company operating in highly populous medical cannabis markets with a mission to deliver the highest standards of cannabis care from nursery to lab to shelf. Headquartered in Miami, FL and operating under the recently-launched Fluent™ brand (formerly Knox Medical), the Company through its subsidiaries operates cultivation, processing and dispensary facilities across Florida, Texas, Puerto Rico and a dispensary license in Pennsylvania. The Company also has licensed cultivation facilities in Colombia and Canada, with licensing pending in Michigan.

Cansortium Inc.’s common shares and warrants trade on the CSE under the symbol “TIUM.U” and “TIUM.WT.U” respectively.

Forward-Looking Information

Certain information in this news release, may constitute forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events.

Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in the public documents of the Company available at These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

For information on Cansortium Inc., please visit

Click Here for More Information »

Starbuds, one of the world’s largest cannabis retailers, continues International growth with expansion into Jamaica

CaribPR Wire, DENVER, March 20, 2019: Starbuds, one of the world’s largest cannabis retailers, is pleased to announce its expansion into Jamaica. With plans to open in late Spring of 2019, Starbuds will become one of only 4 dispensaries to open its doors in the Jamaican capital of Kingston.

Through this licensing agreement, Starbuds will partner with Jamaican native Jonathan Harris to bring its exceptional customer service, industry knowledge and cannabis education to what is often thought of as the mecca of cannabis.

“Jamaica has a reputation as the birthplace of cannabis. It only makes sense that the market will continue to expand through International partnerships with more established companies and Starbuds is proud to be among the first.” says Brian Ruden, founder of Starbuds. “Through our unique owner-operator model, we have been able to provide an unprecedented level of customer service and industry know how while catering to the local demographic of each individual location. We strive to continue this model in Jamaica by pairing our history of experience in the industry with Jonathan’s connection to the community and the island’s affinity for the plant.”

“In Jamaica, I’ve always been surrounded by cannabis,” says Jonathan Harris, Starbuds Jamaica owner operator.  “It wasn’t until I started understanding the medicinal benefits of the plant and what cannabis can actually do, that I fell in love with it. I wanted to share the knowledge with my home country.”

Starbuds Kingston represents Starbuds’ first of many International ventures. Following the opening of Starbuds Kingston, Starbuds and Harris plan to partner on a second licensing agreement, to bring an additional Starbuds location to the Northern Coast of the island.

About Starbuds

Starbuds is changing the way people think about cannabis. Founded in 2013, Starbuds was among the first retail outlets to receive licensing when Colorado legalized recreational cannabis. Starbuds intends to establish its footprint as one of the largest internationally-operating cannabis retail companies.


This communication contains forward-looking statements that involve risks and uncertainties. These forward-looking statements are based on current expectations, estimates and forecasts, as well as the beliefs and assumptions of Starbuds’ management, and are subject to risks and uncertainties that are difficult to predict.  Many factors could cause actual results or events to differ materially from those anticipated, including: risks and uncertainties discussed in this communication. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. We do not assume any obligation to update any forward-looking statements.

Click Here for More Information »

Canopy LATAM starting the year strong – opening new markets, supporting education, and achieving newly licensed production capacity

LIMA, Peru and SMITHS FALLS, Ontario, Jan. 9, 2019 /PRNewswire-HISPANIC PR WIRE/ – Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) (the “Company” or “Canopy Growth”), through its Latin American-focused subsidiary, Canopy LATAM Corporation (”Canopy LATAM”), is proud to introduce Spectrum Cannabis Peru S.A.C. (”Spectrum Cannabis Peru”), the newest member of the growing global Spectrum Cannabis family.

Pictured are: Luiz Orlando Novaes - Country Managing Director, Spectrum Cannabis Peru; Dr. Mark Ware - Chief Medical Officer, Canopy Growth; Antonio Droghetti - Managing Director, Canopy LATAM

Spectrum Cannabis Peru will operate as part of the Canopy LATAM network and with Peru poised to introduce new regulations for the use of medical cannabis, this new in-market entity is uniquely positioned to support the opening of the Peruvian market while leveraging Canopy Growth’s global expertise in patient and physician education, as well as in medical cannabis production.

This announcement directly supports Canopy Growth’s strategy of securing first mover advantage to realize the opportunities generated by evolving cannabis regulations across the region and the world. Until regulations are published supporting patient access to medical cannabis, Spectrum Cannabis Peru will focus on advancing education activities, including working closely with the medical community to foster greater understanding of the potential uses of medical cannabis while reducing stigma.

Supporting education, regulation, and patient access for medical cannabis across Latin America

While in Lima to participate in the launch of Spectrum Cannabis Peru, Dr. Mark Ware, Canopy Growth’s Chief Medical Officer, is advancing the Company’s commitment to education through participation in a range of medical cannabis-focused events for physicians, healthcare professionals, and cannabis-focused patient groups.

This includes addressing healthcare professionals currently attending an introductory course on cannabis held by the medical college of Peru (”Colegio Medico del Peru”), as well as delivering an address and participating in the First Meeting of American Professional Experts working with Phytocannabinoids (”1° Encuentro Americano De Professionales Expertos En Fitocannabioides”) held in Lima from January 10 to 11.

The conference will also see Dr. Ware, in his capacity as a family physician focused on pain management, participate in the signing of the Lima Declaration on the medical use of cannabis. This physician-led declaration encourages governments, regulators, and health authorities throughout the region to ensure patient access and scientific research are the cornerstones of all Latin America medical cannabis laws.

Further, the declaration promotes collaboration across the region, and calls on healthcare professionals to contribute to informed access for cannabis-based medicines while asking patients to advocate and defend their right to such treatments.

A leap forward for sustainable regional production through Spectrum Cannabis Colombia

As previously announced, production operations are advancing at the Company’s farm in Colombia, with initial cultivation having started in late 2018. In line with the plan for sustainable regional production based in the country, the Company is pleased to report that licenses have now been received for the production of cannabis in all 126 hectares (13.6 million sq. ft.) of suitable growing area at the farm.

This is an increase from the previously licensed 42 hectares (4.5 million sq. ft.) of production area and to the Company’s knowledge, the wholly owned farm now represents one of the largest fully licensed cannabis production facilities in the world. This also positions Canopy Growth to meet the emerging regional supply demands as a number of countries across Latin America update their regulations and in so doing, open their markets for the import and sale of Spectrum Cannabis’ high-quality cannabis-based medical products.

Continued development of Canopy LATAM and local in-market entities

As regulations across the region continue to evolve at a rapid pace, Canopy Growth is well positioned to seize these new opportunities through its subsidiary Canopy LATAM, and the in-market entities that work collectively as part of the Company’s LATAM structure. A full leadership team is now in place at both the regional and local level to guide these activities and draws on extensive experience from leading organizations in the pharmaceutical, food and beverage, and consulting industries.

With a fully licensed production site in Colombia, newly launched operations in Peru, a rapidly evolving landscape in Mexico, and clinical trials underway in Chile, Canopy LATAM and Canopy Growth are uniquely positioned to realize the significant opportunities across Latin America with the ultimate goal of serving patients through education and high quality, reliable, medical cannabis products.

Quotes from leadership

“We’re proud to welcome Peru to the growing family of Spectrum Cannabis countries and to have the chance to serve Peruvian patients and healthcare professionals in the future,” said Mark Zekulin, President and Co-CEO, Canopy Growth. “Canopy Growth is a global leader in providing safe, regulated, medical cannabis and by leveraging our experience together with local expertise, we look forward to helping build a responsible Peruvian cannabis industry today and into the future.”

“The landscape for medical cannabis continues to evolve rapidly in Latin America and Peru is poised to take a leading role with the introduction of new regulations which we hope will prioritize patient access”, said Antonio Droghetti, Managing Director, Canopy LATAM. “Launching Peruvian operations enhances our ability to engage with regulators, healthcare professionals, and patients to ensure they have the information they need while also preparing for the future sale of medical cannabis products across the country.”

“With the full licensing of our 126-hectare farm, Spectrum Cannabis Colombia and Canopy Growth have demonstrated yet again our ability to execute and prepare for the rapidly rising demand that exists for medical cannabis”, said Bibiana Rojas, Country Managing Director, Spectrum Cannabis Colombia. “Our ambitious goal of sustainable regional production for medical cannabis is one step closer in Latin America and we’re proud to play a role in increasing the total potential production of Canopy Growth as it builds markets internationally.”

About Canopy Growth Corporation
Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms. Canopy Growth offers the world’s only medically approved vaporizers through the Company’s subsidiary, Storz & Bickel GMbH & Co. KG. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time. The Company has operations in 13 countries across five continents. The Company is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public’s understanding of cannabis, and through its wholly owned subsidiary, Canopy Health Innovations (”Canopy Health”), has devoted millions of dollars toward cutting edge, commercializable research and IP development. Canopy Growth works with the Beckley Foundation and has launched Beckley Canopy Therapeutics to research and develop clinically validated cannabis-based medicines, with a strong focus on intellectual property protection. Canopy Growth acquired assets of leading hemp research company, ebbu, Inc. (”ebbu”). Intellectual Property (”IP”) and R&D advancements achieved by ebbu’s team apply directly to Canopy Growth’s hemp and THC-rich cannabis genetic breeding program and its cannabis-infused beverage capabilities. Through partly owned subsidiary Canopy Rivers Corporation, the Company is providing resources and investment to new market entrants and building a portfolio of stable investments in the sector. From our historic public listing on the Toronto Stock Exchange and New York Stock Exchange to our continued international expansion, pride in advancing shareholder value through leadership is engrained in all we do at Canopy Growth. Canopy Growth has established partnerships with leading sector names including cannabis icon Snoop Dogg, breeding legends DNA Genetics and Green House seeds, Battelle, the world’s largest nonprofit research and development organization, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates ten licensed cannabis production sites with over 4.3 million square feet of production capacity, including over 500,000 square feet of GMP certified production space. The Company operates Tweed retail stores in Newfoundland and Manitoba and has entered into supply agreements with every Canadian province and territory. For more information visit

Notice Regarding Forward Looking Statements
This news release contains “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. Examples of such statements include statements with respect to international operations in the LATAM region. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including the Company’s ability to satisfy provincial sales contracts or provinces purchasing all cannabis allocated to them, and such risks contained in the Company’s annual information form dated June 27, 2018 and filed with Canadian securities regulators available on the Company’s issuer profile on SEDAR at Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

Photo -

Click Here for More Information »

Global Canna Labs Invests US$1M into Zimmer & Co. Strategic Partnership with Jamaican Health & Wellness Distribution Company



*For Immediate Release*

 Jamaican company Global Canna Labs (“GCL”) is pleased to announce a US$1M investment through its partners LGC Capital (“LGC”) via a convertible note into Zimmer & Co. Limited (“Zimmer”).

Jamaican company Global Canna Labs (“GCL”) is pleased to announce a US$1M investment through its partners LGC Capital (“LGC”) via a convertible note into Zimmer & Co. Limited (“Zimmer”).

CaribPR Wire, MONTEGO BAY, Mon. July 30, 2018. Jamaican company Global Canna Labs (“GCL”) is pleased to announce a US$1M investment through its partners LGC Capital (“LGC”) via a convertible note into Zimmer & Co. Limited (“Zimmer”).  The capital will be used to finance Zimmer’s expansion and accelerate its plans to distribute quality health and wellness products in Jamaica and the rest of the Caribbean, as well into Colombia, Mexico, Canada and throughout Europe.

Zimmer is a Jamaica based health and wellness distribution company with its offices in Montego Bay. The company has received its pharmacy wholesale distribution license which permits legal sale to pharmacies, doctors and hospitals on the island.  The company currently distributes a portfolio of just over 50 hemp-based CBD products ranging from oils to skincare.  Since commencing sales a few weeks ago, the company has quickly established itself as a key player in the burgeoning Jamaican market with sales into over 50 of the leading pharmacies on the island for its portfolio of approved products. Zimmer has emerged as a dominant player in this new category and currently has distribution agreements representing 50 of the 61 products that have been approved for sale in Jamaica.

Global Canna Labs is one of the leading medical cannabis companies in Jamaica, having recently been granted its full Tier 3 operator’s licence on its 270,000 square foot facility in the heart of Montego Bay, Jamaica. The Tier 3 licence is the largest issued license by the Jamaican Cannabis License Authority (CLA). GCL is backed by Canadian listed LGC Capital Limited.

Zimmer CEO, T’Shura Gibbs believes that the medicinal cannabis market holds tremendous potential for the Caribbean nation: “As the industry evolves, we welcome the significant job creation and economic value that will be derived.  I am excited about this tremendous opportunity with GCL. This collaboration does not only bode well for our growth and development as an organization, but it allows us, in partnership, to move Jamaica directly into the critical finished goods segment of the industry where we can manufacture products in Jamaica and export globally.  The ‘Made in Jamaica’ brand is very strong, and we feel that this particular partnership combining quality Jamaican products with established, world-class formulations that have been approved in a number of key global markets affords us a tremendous opportunity.”

The investment will facilitate Zimmer’s business expansion into new markets and retail points while providing access to additional products through its distribution channels.  As a local producer this will afford GCL an additional revenue stream, directly into finished products via Zimmer’s product portfolio.

Global CEO, Paul Glavine: “This is a strategic partnership that will help GCL push its future product line throughout Caribbean and Central American countries as the industry rapidly develops. It allows GCL to focus on producing safe and secure products while Zimmer safely distributes and delivers the products to the end consumers.”

Owen Ellington from Global said: “This new partnership with Zimmer will afford us direct entry into the value chain of finished products and provide both companies with new sales revenue streams for ‘Made in Jamaica’ products.  Zimmer has an impressive portfolio of high-quality products and we are excited by this partnership and the opportunity to incorporate our oils into these and other finished goods they will be distributing.  This partnership provides an additional growth opportunity for GCL which translates into more jobs in Jamaica and contributes positively to the Jamaican economy, especially in agriculture and manufacturing sectors and allows us to increase productive growing capacity.”


About Zimmer & Co. (

Zimmer & Co. is a health and wellness distribution enterprise focused on medicinal cannabis and hemp-based products.  Zimmer’s primary market is the Caribbean where the principals have almost 50 combined professional years encompassing sales, marketing, business development, entrepreneurship, management and customer service.  Zimmer has a growing portfolio of products and plays an active role in the development of the industry in Jamaica by supporting advocacy, education and small business initiatives that will see the industry rise as an economic force and significant contributor to the economies of the Caribbean.

For further information please contact:

Paul Glavine (CEO)

Global Canna Labs

[email protected]

(647) 500-4796

T’Shura Gibbs (CEO)

Zimmer & Co.

[email protected]

(876) 633-0377

Click Here for More Information »